Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland.
Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland.
复制标题
DOI：
10.1016/j.dadr.2023.100184
复制
发表时间：
2023-09
期刊：
影响因子：
--
通讯作者：
Laeyendecker, Oliver
中科院分区：
文献类型：
--
作者：
Patel, Eshan U;Mehta, Shruti H;Genberg, Becky L;Baker, Owen R;Schluth, Catherine G;Astemborski, Jacquie;Fernandez, Reinaldo E;Quinn, Thomas C;Kirk, Gregory D;Laeyendecker, Oliver
感染引起的 SARS-CoV-2 抗体的患病率为 26%。感染和/或疫苗接种诱导的 SARS-CoV-2 抗体的患病率为 63%。 SARS-CoV-2 抗体的流行率和强度随着时间的推移而增加。药物使用相关行为与 SARS-CoV-2 抗体无关。血清流行率的差异凸显了需要加大疫苗接种力度的群体。 SARS-CoV-2 血清调查可以帮助描述 SARS-CoV-2 感染的差异并确定人群免疫力的差距。有关注射吸毒者 (PWID) 中 SARS-CoV-2 血清流行率的数据有限。我们于 2020 年 12 月至 2022 年 7 月期间对 561 名艾滋病相关静脉注射经历 (ALIVE) 研究参与者进行了一项横断面研究，该研究是马里兰州巴尔的摩当前和前注射吸毒者的社区队列。检测血清样本中感染诱导的抗核衣壳（抗 N）和感染和/或疫苗接种诱导的抗 Spike-1（抗 S）SARS-CoV-2 IgG。我们通过修正的泊松回归模型估计了调整后的患病率（aPR）。中位年龄为 59 岁，35% 为女性，84% 为非西班牙裔黑人，16% 报告最近注射毒品。抗 N 抗体患病率为 26%，抗 S 抗体患病率为 63%。抗 N 和抗 S 抗体的流行率随着时间的推移而增加。受雇 (aPR=1.53 [95%CI=1.11–2.11]) 与较高的抗 N 患病率相关，而癌症病史 (aPR=0.40 [95%CI=0.17–0.90]) 与较低的抗 N 患病率相关。 HIV 感染与较高的抗 S 患病率相关（aPR=1.13 [95%CI=1.02–1.27]），而年龄较小和无家可归（aPR=0.78 [95%CI=0.60–0.99]）是与较低的抗 S 患病率相关的因素。物质使用相关行为与抗 N 或抗 S 患病率没有显着相关。在当前和以前的注射吸毒者中，SARS-CoV-2 血清流行率随着时间的推移而增加，这表明 SARS-CoV-2 感染和疫苗接种的发生率不断增加；然而，本研究样本中感染引起的血清流行率与感染和/或疫苗引起的血清流行率存在差异。需要专门的预防和疫苗接种计划，以防止新出现的流行病期间吸毒者之间的感染差异和人群免疫力的差距。
Prevalence of infection-induced SARS-CoV-2 antibodies was 26%. Prevalence of infection and/or vaccination-induced SARS-CoV-2 antibodies was 63%. The prevalence and magnitude of SARS-CoV-2 antibodies increased over time. Substance use-related behaviors were not associated with SARS-CoV-2 antibodies. Disparities in seroprevalence highlighted groups that need greater vaccine efforts. SARS-CoV-2 serosurveys can help characterize disparities in SARS-CoV-2 infection and identify gaps in population immunity. Data on SARS-CoV-2 seroprevalence among people who inject drugs (PWID) are limited. We conducted a cross-sectional study between December 2020 and July 2022 among 561 participants in the AIDS Linked to the IntraVenous Experience (ALIVE) study—a community-based cohort of current and former PWID in Baltimore, Maryland. Serum samples were assayed for infection-induced anti-nucleocapsid (anti-N) and infection and/or vaccination-induced anti-spike-1 (anti-S) SARS-CoV-2 IgG. We estimated adjusted prevalence ratios (aPR) via modified Poisson regression models. The median age was 59 years, 35% were female, 84% were non-Hispanic Black, and 16% reported recent injection drug use. Anti-N antibody prevalence was 26% and anti-S antibody prevalence was 63%. Anti-N and anti-S antibody prevalence increased over time. Being employed (aPR=1.53 [95%CI=1.11–2.11]) was associated with higher anti-N prevalence, while a cancer history (aPR=0.40 [95%CI=0.17–0.90]) was associated with lower anti-N prevalence. HIV infection was associated with higher anti-S prevalence (aPR=1.13 [95%CI=1.02–1.27]), while younger age and experiencing homelessness (aPR=0.78 [95%CI=0.60–0.99]) were factors associated with lower anti-S prevalence. Substance use-related behaviors were not significantly associated with anti-N or anti-S prevalence. SARS-CoV-2 seroprevalence increased over time among current and former PWID, suggesting cumulative increases in the incidence of SARS-CoV-2 infection and vaccination; however, there were disparities in infection-induced seroprevalence and infection and/or vaccine-induced seroprevalence within this study sample. Dedicated prevention and vaccination programs are needed to prevent disparities in infection and gaps in population immunity among PWID during emerging epidemics.
影响因子：
4.4
作者：
Doshi, Shradha;Kingston, Hanley;Tseng, Ashley S. S.;Chohan, Bhavna H. H.;Sambai, Betsy;Guthrie, Brandon L. L.;Monroe-Wise, Aliza;Mbogo, Loice W. W.;Masyuko, Sarah;Tram, Khai Hoan;Sinkele, William;Macharia, Paul;Bukusi, David;Herbeck, Joshua T. T.;Farquhar, Carey
通讯作者：
Farquhar, Carey
影响因子：
4.4
作者：
Carroll, Jennifer J.;Rossi, Sarah L.;Vetrova, Marina V.;Blokhina, Elena;Sereda, Yuliia;Lioznov, Dmitry;Luoma, Jason;Kiriazova, Tetiana;Lunze, Karsten
通讯作者：
Lunze, Karsten